News | February 03, 2014

Thorne Research, WellnessFX, Itamar Enter 3-Year Agreement for EndoPAT

Thorne Research Itamar Medical EndoPAT WatchPAT Cardiac Diagnostics
February 3, 2014 — Thorne Research Inc. and Itamar Medical Inc. entered into a three-year non-exclusive agreement to co-market Itamar's EndoPAT and WatchPat. EndoPat is a device to assess arterial (endothelial) function, and WatchPAT is a home-based sleep test to diagnose obstructive sleep apnea. The U.S. Food and Drug Administration (FDA) have cleared both.
 
Under the agreement, Thorne Research will receive marketing rights for the EndoPAT and WatchPAT devices and related disposables (finger probes) in the United States. Thorne Research will incorporate EndoPAT and WatchPAT training materials into its training events for healthcare practitioners.
 
The Hypertension Institute, Thorne Research and Itamar collaborate to provide cardiovascular research services and clinical evaluation to practitioners for the early identification of cardiovascular issues that will direct optimal support and related therapies.
 
For more information: www.thorne.com

Related Content

AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG| August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
New Study Focuses on Protein Responsible For Increased Heart Disease Risk
News | Cardiac Diagnostics| August 03, 2017
August 3, 2017 — A study to reduce the strongest inherited...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Aug.
Philips released a new version of its iFR system that displays FFR readings as an overlay on live angiographic, angiogram images.

Philips released a new version of its iFR system that displays hemodynamic pressure drop points in an overlay on live angiographic images, matching up the iFR readings with corresponding lesions. The system is supposed to speed diagnostic decision making and help guide percutaneous revascularization procedures. 

Feature | FFR Catheters| July 31, 2017 | Dave Fornell
The gold standard for assessing the hemodynamic significance or coronary lesions to determine if they should be revas
Siemens Healthineers to Acquire Epocal from Alere
News | Point of Care Testing| July 26, 2017
Siemens Healthineers has entered into a definitive agreement to acquire Epocal Inc., a subsidiary of Alere Inc. Epocal...
New PET-CT Scan Improves Detection in Rare Cardiac Condition
News | PET-CT| July 25, 2017
Using a new imaging technique that can diagnose cardiac sarcoidosis much more accurately than traditional tests,...
3-D Vascular Ultrasound Quantifies Plaque Burden to Estimate Cardiovascular Risk
News | Cardiovascular Ultrasound| July 20, 2017
July 20, 2017 — In a large, first-of-its-kind population, researchers found an experimental technique known as...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG| July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Alere point of care POC testing for INR
News | Point of Care Testing| July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
Overlay Init